1. Home
  2. Stocks
  3. Marksans Share Price

Marksans Pharma Share Price

Pharmaceuticals Mid Cap

₹290.55 +3.65 (1.27%)

05 Nov, 2024 21:55

SIP TrendupStart SIP in MARKSANS

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹283
  • High
  • ₹295
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹329
  • Open Price₹284
  • Previous Close₹287
  • Volume1,168,692

Investment Returns

  • Over 1 Month + 0.26%
  • Over 3 Month + 41.41%
  • Over 6 Month + 75.08%
  • Over 1 Year + 158.04%
SIP Lightning

Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!

Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 39.4
  • PEG Ratio
  • 1.9
  • Market Cap Cr
  • 13,167
  • P/B Ratio
  • 6.3
  • Average True Range
  • 12.96
  • EPS
  • 3
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 0.78
  • RSI
  • 55.62
  • MFI
  • 42.94

Marksans Pharma Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations254.53225.20241.36204.67182.04
Total Income From Operations254.53225.20241.36204.67182.04
P/L Before Interest, Excpt. Items & Tax42.5838.6334.8744.7354.66
P/L Before Exceptional Items & Tax42.3038.4034.6044.5054.40
P/L After Tax from Ordinary Activities32.0232.9925.2931.2944.19
Net Profit/Loss For the Period32.0232.9925.2931.2944.19
IndicatorMar 24Mar 23
Revenue From Operations [Gross]850.06652.68
Revenue From Operations [Net]850.06652.68
Total Operating Revenues853.27655.20
Total Revenue915.35715.69
Total Expenses743.45583.65
Profit/Loss Before Tax171.89132.04
Profit/Loss For The Period133.76102.87
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity34.0551.73
Net Cash Used In Investing Activity-114.22-194.62
Net Cash Used in Finance Activity-26.22210.02
Net Inc/Dec In Cash And Equivalent-106.3867.12
Cash And Equivalent End Of Year41.93148.31
IndicatorMar 24Mar 23
Total Share Capital45.3245.32
Total Non-Current Liabilities20.9017.00
Total Current Liabilities272.44216.54
Total Capital And Liabilities1,516.041,344.86
Total Non-Current Assets568.33431.10
Total Current Assets947.70913.76
Total Assets1,516.041,344.86
Indicator20242023
EBIT Margin (%)20.2620.70
Return On Capital Employed (%)13.9012.02
Return On Equity (%)10.939.25
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)26.9824.52
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations590.62560.01586.13531.24500.03
Total Income From Operations590.62560.01586.13531.24500.03
P/L Before Interest, Excpt. Items & Tax122.94105.12115.82115.3998.40
P/L Before Exceptional Items & Tax120.02100.28112.66113.7796.83
P/L After Tax from Ordinary Activities89.0777.6482.9783.8570.44
Net Profit/Loss For the Period89.0777.6482.9783.8570.44
IndicatorMar 24Mar 23
Revenue From Operations [Gross]2,174.201,849.62
Revenue From Operations [Net]2,174.201,849.62
Total Operating Revenues2,177.411,852.14
Total Revenue2,227.831,911.45
Total Expenses1,804.301,573.80
Profit/Loss Before Tax423.53337.65
Profit/Loss For The Period314.90265.32
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity230.41237.41
Net Cash Used In Investing Activity-140.84-259.21
Net Cash Used in Finance Activity-68.73197.83
Net Inc/Dec In Cash And Equivalent20.84176.03
Cash And Equivalent End Of Year403.28382.44
IndicatorMar 24Mar 23
Total Share Capital45.3245.32
Total Non-Current Liabilities205.2084.33
Total Current Liabilities389.85340.99
Total Capital And Liabilities2,680.952,190.39
Total Non-Current Assets818.46515.09
Total Current Assets1,862.491,675.30
Total Assets2,680.952,190.39
Indicator20242023
EBIT Margin (%)19.9618.72
Return On Capital Employed (%)18.9718.75
Return On Equity (%)15.1915.25
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)46.0338.95

Marksans Pharma Technicals

EMA & SMA

Current Price
₹290.55
+ 3.65 (1.27%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹282.58
  • 50 Day
  • ₹270.67
  • 100 Day
  • ₹244.21
  • 200 Day
  • ₹208.64

Resistance and Support

289.57 Pivot Speed
  • R3 307.83
  • R2 301.42
  • R1 295.98
  • S1 284.13
  • S2 277.72
  • S3 272.28

Is Marksans Pharma Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Marksans Pharma Ltd. is a global pharmaceutical company engaged in the research, development, and manufacturing of generic drugs. It offers a wide range of pharmaceutical formulations, serving key therapeutic areas such as pain management, cardiovascular, and gastrointestinal. Marksans Pharma has an operating revenue of Rs. 2,267.99 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 49% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 79 which is a FAIR score but needs to improve its earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Marksans Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results & Final Dividend
2024-02-13 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend

Marksans Pharma F&O

Marksans Pharma Shareholding Pattern

43.87%
3.02%
10.43%
0%
26.76%
15.92%
  • NSE Symbol
  • MARKSANS
  • BSE Symbol
  • 524404
  • Chairman & Managing Director
  • Mr. Mark Saldanha
  • ISIN
  • INE750C01026

Marksans Pharma FAQs

Marksans Pharma share price is ₹290 As on 05 November, 2024 | 21:41

The Market Cap of Marksans Pharma is ₹13166.7 Cr As on 05 November, 2024 | 21:41

The P/E ratio of Marksans Pharma is 39.4 As on 05 November, 2024 | 21:41

The PB ratio of Marksans Pharma is 6.3 As on 05 November, 2024 | 21:41

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.